Novo Nordisk Using Priority Review Voucher To Propel Oral Semaglutide To Market

Danish diabetes fighter will file oral semaglutide with FDA within months using a priority review voucher to reduce the time for expected approval to six months.

Track
Novo Nordisk Aims to cut FDA review time to six months for its oral GLP-1. • Source: Shutterstock

Prospects of a 2020 market arrival for Novo Nordisk AS’s ground-breaking oral GLP-1 diabetes therapy remain on track, propelled by solid clinical trial data and a priority review voucher purchased by the Denmark-based group to speed the process.

Regulatory plans for oral semaglutide were announced along with the company’s fourth-quarter and full-year update for fiscal 2018, which although...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip